PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 23, Issue 8, Pages 2034-2042
Publisher
Oxford University Press (OUP)
Online
2011-12-16
DOI
10.1093/annonc/mdr546
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Biologic markers determine both the risk and the timing of recurrence in breast cancer
- (2011) Laura J. Esserman et al. BREAST CANCER RESEARCH AND TREATMENT
- Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer
- (2011) E. Razis et al. BREAST CANCER RESEARCH AND TREATMENT
- Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
- (2011) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- PTEN, PIK3CA, p-AKT, and p-p70S6K Status
- (2010) Francisco J. Esteva et al. AMERICAN JOURNAL OF PATHOLOGY
- Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer
- (2010) R. B. Costa et al. ANNALS OF ONCOLOGY
- PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer
- (2010) J. Dupont Jensen et al. CLINICAL CANCER RESEARCH
- Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast Cancers
- (2010) Bhuvanesh Dave et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of Sanger Sequencing, Pyrosequencing, and Melting Curve Analysis for the Detection of KRAS Mutations
- (2010) Athanasios C. Tsiatis et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
- (2010) N. A. O'Brien et al. MOLECULAR CANCER THERAPEUTICS
- Protocol for PTEN Expression by Immunohistochemistry in Formalin-fixed Paraffin-embedded Human Breast Carcinoma
- (2010) Rita A. Sakr et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab
- (2009) S. Gori et al. ANNALS OF ONCOLOGY
- Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
- (2009) Y. Kataoka et al. ANNALS OF ONCOLOGY
- Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer
- (2009) Matthew J. Ellis et al. BREAST CANCER RESEARCH AND TREATMENT
- Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab
- (2009) D. Faratian et al. CANCER RESEARCH
- PIK3CA Mutation Associates with Improved Outcome in Breast Cancer
- (2009) K. Kalinsky et al. CLINICAL CANCER RESEARCH
- Resistance to Trastuzumab in Breast Cancer
- (2009) P. R. Pohlmann et al. CLINICAL CANCER RESEARCH
- Molecular predictors of response to trastuzumab and lapatinib in breast cancer
- (2009) Francisco J. Esteva et al. Nature Reviews Clinical Oncology
- Evaluation of and quality assurance in HER2 analysis in breast carcinomas from patients registered in Danish Breast Cancer Group (DBCG) in the period of 2002–2006. A nationwide study including correlation between HER-2 status and other prognostic variables
- (2008) Birgitte Bruun Rasmussen et al. ACTA ONCOLOGICA
- PIK3CA Exon 20 Mutation is Independently Associated with a Poor Prognosis in Breast Cancer Patients
- (2008) Yuen-Liang Lai et al. ANNALS OF SURGICAL ONCOLOGY
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
- (2008) K. Stemke-Hale et al. CANCER RESEARCH
- Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
- (2008) P. J.A. Eichhorn et al. CANCER RESEARCH
- Circumventing De Novo and Acquired Resistance to Trastuzumab: New Hope for the Care of ErbB2-Positive Breast Cancer
- (2008) Martine Piccart Clinical Breast Cancer
- The role of PTEN signaling perturbations in cancer and in targeted therapy
- (2008) M Keniry et al. ONCOGENE
- PI3K pathway alterations in cancer: variations on a theme
- (2008) T L Yuan et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now